ClinicaliQ Trial Snapshot
- A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS) — Active Not Recruiting • Phase III • Neurology • NCT05123703.
- Ocrelizumab versus fingolimod for treating multiple sclerosis in children and teenagers over 24 weeks.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This double-blind, double-dummy study will evaluate the safety and efficacy of ocrelizumab compared with fingolimod in children and adolescents with RRMS aged between 10 and < 18 years over a flexible duration. The double-blind period will last until after the last participant randomized has completed 24 weeks. Conditions: Relapsing-remitting Multiple Sclerosis Interventions: Ocrelizumab, Ocrelizumab Placebo, Fingolimod, Fingolimod Placebo Lead Sponsor: Hoffmann-La Roche Planned Enrollment: 188 participants